期刊文献+

静脉用右旋糖酐铁经透析器清除的研究 被引量:1

Removal of iron dextran during hemodialysis with polysulfone F6 and homophone GFSplus12
在线阅读 下载PDF
导出
摘要 目的:了解血液透析病人静脉滴注(静滴)右旋糖酐铁后,元素铁经透析器的清除情况。方法:6例稳定的维持性血液透析病人,均在透析h2开始静滴右旋糖酐铁100mg,时间大于30min。6例病人分别使用F6透析器和GFSplus12透析器,取新鲜透析液作为空白液,透析h1的废透析液作为对照液。测定空白液、对照液和静滴开始后至透析结束时所有的废透析液中铁的含量。结果:空白液和对照液的铁浓度分别为0. 82, (4. 3±s2. 6)μg·L-1;静脉输入右旋糖酐铁后,使用F6透析器和GFS plus12透析器时透析液中铁浓度分别为( 12±6 ),(15±7)μg·L-1,均高于对照液中铁浓度(P<0. 05,P<0. 01)。对铁的总清除量最大为2. 40mg,小于输入量的3%。结论:血液透析中使用F6透析器和GFSplus12透析器对右旋糖酐铁的清除很微量,利用率高。 AIM: To measure the removal of iron dextran in patients undergone hemodialysis. METHODS: Six patients undergone hemodialysis receiving iron dextran 100 mg intravenously for 30 min during h 2 of dialysis. All patients received F6 (polysulphone membrane) and GFSplus12 ( hemophone membrane) dialyzers, separately. A baseline sample of fresh dialysate was collected before the initiation of dialysis. A control sample of spent dialysate was collected during the first hour of dialysis before the infusion of iron dextran. And then, the spent dialysate was again collected from infusing iron dextran until the end of dialysis. The samples were dealed with lanthanum nitrate solution, and then measured by atomic absorptive spectrum method. RESULTS: The iron concentrations at baseline and in control samples were 0.82 and (4.3± s 2.6)μg·L -1. After intravenous infusion of iron dextran, the iron concentration in the spent dialysate increased significantly. The results showed F6 dialyzer ((12±6)μg·L -1, P<0.05) or GFSplus12 dialyzer ((15±7)μg·L -1, P<0.01) , with minimal amount of iron eliminated through the dialyzers. i.e. less than 3 % of infusion dose outcoming with no obvious difference in the removal of iron for both F6 and GFSplus12 dialyzers. CONCLUSION: The removal of iron dextran by hemodialysis with F6 and GFSplus12 dialysers is minimal demonstrating the efficiency and convenience of the two dialyzers.
作者 陈育青 王梅
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2005年第4期305-307,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 铁右旋糖酐复合物 肾透析 贫血 iron-dextran complex renal dialysis anemia
  • 相关文献

参考文献3

二级参考文献5

  • 1FLETES R, LAZARUS J M, GAGE J, et al. Suspected iron dextran-related adverse drug events in hemodialysis patients[J ]. Am J Kidney Dis, 2001,37(4) :743-749.
  • 2HORLWH. Should we still use iron dextran in hemodialysis patients? [J]. Am J Kidney Dis, 2001, 37(4) :859-861.
  • 3MARKOWITZ GS, KAHN GA, FEINGOLD RE, et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin [ J ]. Clin Nephrol, 1997,48( 1 ) :34-40.
  • 4MACDOUGALL IC, TUCKER B, THOMPSON J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin[ J ]. Kidney Int, 1996,50(5) : 1694-1699.
  • 5FISHBANE S, FREI GL, MAESAKA J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation[J]. Am J Kidney Dis, 1995,26(1) :41-46.

共引文献69

同被引文献6

  • 1唐琦,汪关煜,钱莹,朱萍,沈平雁.肾性贫血时静脉与口服铁剂的疗效比较[J].中国血液净化,2004,3(8):431-434. 被引量:38
  • 2KOPPLE JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic kidney disease[ J]. Am J Kidney Dis, 2001, 37(1 Suppl 2) : S66-S70.
  • 3SILVERBERG DS, BLURN M, AGBARIA Z, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period[J]. Clin Nephrol, 2001, 55(3) :212-219.
  • 4FISHBANE S, MAESAKA JK. Iron management in end-stage renal disease[J]. Am J Kidney Dis, 1997, 29(3) :319-333.
  • 5AHSAN N, GROFF JA, WAYBILL MA. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin [ J ]. Adv Perit Dial, 1996,12:161-166.
  • 6FISHBANE S. Safety in iron management [ J ]. Am J Kidney Dis,2003, 41(5 Suppl) :18-26.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部